Press 2/2

MYND Life Sciences to Present at H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Confe

Jun 15, 2021

MYND Life Sciences to Present at H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Confe

VANCOUVER, BC, June 15, 2021 /PRNewswire/ – MYND Life Sciences Inc. (CSE: MYND) (“MYND“) a drug research and development company focused...

Mynd Life Sciences

Jun 10, 2021

MYND Life Sciences Announces Patent Applications for Depression and Neuropsychiatric Disorder Drugs

VANCOUVER, BC, June 10, 2021 /CNW/ – MYND Life Sciences Inc. (CSE: MYND) (“MYND“) a drug research and development company focused on...

Mynd Life Sciences

Jun 1, 2021

MYND Life Sciences announces Depression Biomarker Diagnostic Program

VANCOUVER, BC, June 1, 2021 /CNW/ – MYND Life Sciences Inc. (CSE: MYND) (“MYND“) a drug research and development company focused on novel...

Mynd Life Sciences

May 28, 2021

MYND Life Sciences Inc. Establishes Scientific Advisory Board

VANCOUVER, BC, May 28, 2021 /CNW/ – MYND Life Sciences Inc. (CSE: MYND) (“MYND“), a drug research and development company focused on...

Mynd Life Sciences

May 26, 2021

MYND Life Sciences Inc. Announces Public Listing on the Canadian Securities Exchange

VANCOUVER, BC, May 26, 2021 /PRNewswire/ – MYND Life Sciences Inc. (“MYND”), a life sciences company focused on novel psychedelic drug...

Mynd Life Sciences

May 18, 2021

MYND Life Sciences Inc. Announces Filing of Final Prospectus and Canadian Securities Exchange Condit

VANCOUVER, May 18, 2021 /PRNewswire/ – MYND Life Sciences Inc. (the “Company” or “MYND“) a life sciences company focused on novel...

Mynd Life Sciences

Feb 2, 2021

MYND Life Sciences Inc. Announces Collaborative Research Agreement with the University of British Co

VANCOUVER, BC, Feb. 2, 2021 /PRNewswire/ – MYND Life Sciences Inc. (“MYND“) a life sciences company focused on novel psychedelic drug...

Mynd Life Sciences

Feb 1, 2021

MYND Life Sciences CEO Invited to Present at Canaccord Genuity’s New Paradigms and Treatment A

VANCOUVER, BC, Feb. 1, 2021 /CNW/ – MYND Life Sciences Inc. (“MYND“) a life sciences company focused on novel psychedelic drug...

Mynd Life Sciences

Jan 7, 2021

MYND Life Sciences Inc. Closes $2.4 Million Private Placement and Provides Update on Planned Listing

VANCOUVER, BC, Jan. 7, 2021 /CNW/ – MYND Life Sciences Inc. (“MYND“) a life sciences company focused on novel psychedelic drug...

MENU

MYND Life Sciences to Present at H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Confe

MYND Life Sciences Announces Patent Applications for Depression and Neuropsychiatric Disorder Drugs

MYND Life Sciences announces Depression Biomarker Diagnostic Program

MYND Life Sciences Inc. Establishes Scientific Advisory Board

MYND Life Sciences Inc. Announces Public Listing on the Canadian Securities Exchange

MYND Life Sciences Inc. Announces Filing of Final Prospectus and Canadian Securities Exchange Condit

MYND Life Sciences Inc. Announces Collaborative Research Agreement with the University of British Co

MYND Life Sciences CEO Invited to Present at Canaccord Genuity’s New Paradigms and Treatment A

MYND Life Sciences Inc. Closes $2.4 Million Private Placement and Provides Update on Planned Listing

DIAGNOSTICS
INVESTING
SCIENCE

CONTACT
NEWS

MENU

MYND Life Sciences to Present at H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Confe

MYND Life Sciences Announces Patent Applications for Depression and Neuropsychiatric Disorder Drugs

MYND Life Sciences announces Depression Biomarker Diagnostic Program

MYND Life Sciences Inc. Establishes Scientific Advisory Board

MYND Life Sciences Inc. Announces Public Listing on the Canadian Securities Exchange

MYND Life Sciences Inc. Announces Filing of Final Prospectus and Canadian Securities Exchange Condit

MYND Life Sciences Inc. Announces Collaborative Research Agreement with the University of British Co

MYND Life Sciences CEO Invited to Present at Canaccord Genuity’s New Paradigms and Treatment A

MYND Life Sciences Inc. Closes $2.4 Million Private Placement and Provides Update on Planned Listing

DIAGNOSTICS INVESTING SCIENCE

CONTACT NEWS

DIAGNOSTICS
INVESTING
SCIENCE

CONTACT
NEWS